Anti-SYT1 Antibody, clone 1F11 ZooMAb^® Rabbit Monoclonal

Synaptotagmin-1(UniProt: P21579; also known as Synaptotagmin I, SytI, p65) is encoded by the SYT1 (also known as SVP65, SYT) gene (Gene ID: 6857) in human. Synaptotagmin binds Ca2+ phospholipids with high affinity and has a central role in Ca2+ regulated neurotransmitter release by mediating both synchronous and asynchronous fusion processes. It functions as a Ca2+ sensor and is required for efficient exocytosis, particularly in the vesicle docking and/or fusion step with the plasma membrane. Ca2+ influx triggers synaptotagmin to interact with either syntaxin or SNAP-25 and the cytoplasmic domain of neurexin leading to fusion and exocytosis. Synaptotagmin is an abundant synaptic vesicle (SV) single-pass membrane protein. It is characterized by a short intravesicular N-terminal domain (aa 1-57), a transmembrane domain (aa 58-80) and two copies of highly conserved internal repeats, known as the C2A and C2B domains, which are homologous to the C2 regulatory region of protein kinase C (PKC) in the cytoplasmic domain (aa 81-422). At least eight different isoforms of synaptotagmin (SytI-VIII) are expressed in the brain, four of which (Syt IV, V, VII and VIII) are also expressed in non-neuronal tissues. In synaptic vesicles, synaptotagmin-12 associates with SYT1 and prevents SYT1 interaction with soluble NSF attachment protein receptor (SNARE) complexes. When Ca2+ binds to SYT1, the exocytosis of synaptic vesicles (which have been prepared for release by SNARE-complex assembly) is triggered. Mutations or deletion of synaptotagmin result in severely impaired Ca2+ triggered neurotransmitter release. Dysregulation of SYT1 has been implicated in movement disorders, behavioral disturbances, neurological disorders, including Baker-Gordon Syndrome and intellectual disabilities, underscoring its importance in maintaining synaptic integrity and neuronal communication. This ZooMAb^® recombinant monoclonal antibody, generated by our proprietary technology, offers significantly enhanced specificity, affinity, reproducibility, and stability over conventional monoclonals. (Ref.: Fernandez-Chacon, R., et al. (2001). Nature. 410(6816); 41-49; van Boven, M.A., et al. (2024). Mol Psychiatry. 29;1798-1809).

Quality Control Testing

Evaluated by Western Blotting in human brain tissue lysate.

Western Blotting Analysis: A 1:1,000 dilution of this antibody detected SYT1 in human brain tissue lysate.

Tested Applications

Western Blotting Analysis: A 1:1,000 dilution from a representative lot detected SYT1 in lysate from mouse brain tissue.

Affinity Binding Assay: A representative lot of this antibody bound SYT1 peptide with at least ten thousand-fold (10,000X) higher affinity than with non-specific control peptide.

Immunohistochemistry (Paraffin) Analysis: A 1:100 dilution from a representative lot detected SYT-1 in human cerebral cortex tissue sections.

Note: Actual optimal working dilutions must be determined by end user as specimens, and experimental conditions may vary with the end user.

Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.

ZooMAb^® antibodies represent an entirely new generation of recombinant monoclonal antibodies. Each ZooMAb^® antibody is manufactured using our proprietary recombinant expression system, purified to homogeneity, and precisely dispensed to produce robust and highly reproducible lot-to-lot consistency. Only top-performing clones are released for use by researchers. Each antibody is validated for high specificity and affinity across multiple applications, including its most commonly used application. ZooMAb^® antibodies are reliably available and ready to ship when you need them.

KLH-conjugated linear peptide corresponding to 25 amino acids from the N-terminal half of human Synaptotagmin-1 (SYT1).

Clone 1F11 is a ZooMAb^® recombinant rabbit monoclonal antibody that specifically detects Synaptotagmin-1 (SYT1). It targets an epitope within 25 amino acids from the N-terminal half.

Purified recombinant rabbit monoclonal antibody IgG, lyophilized in PBS with 5% Trehalose, normal appearance a coarse or translucent resin. The PBS/trehalose components in the ZooMAb formulation can have the appearance of a semi-solid (bead like gel) after lyophilization. This is a normal phenomenon. Please follow the recommended reconstitution procedure in the data sheet to dissolve the semi-solid, bead-like, gel-appearing material. The resulting antibody solution is completely stable and functional as proven by full functional testing. Contains no biocide or preservatives, such as azide, or any animal by-products. Larger pack sizes provided as multiples of 25 µL.

300 µg/mL after reconstitution at 25 µL per vial. Please refer to guidance on suggested starting dilutions and/or titers per application and sample type.

Recommend storage of lyophilized product at 2-8°C; Before reconstitution, micro-centrifuge vials briefly to spin down material to bottom of the vial; Reconstitute each vial by adding 25 µL of filtered lab grade water or PBS; Reconstituted antibodies can be stored at 2-8°C, or -20°C for long term storage. Avoid repeated freeze-thaws.

ZooMAb is a registered trademark of Merck KGaA, Darmstadt, Germany